Einstein/Montefiore Department of Medicine

Department Faculty

Dr. Amit K. Verma, M.B.B.S.

Amit K. Verma, M.B.B.S.

Professor, Department of Medicine (Oncology)

Professor, Department of Developmental & Molecular Biology

Areas of Research: Myelodysplastic syndrome (MDS) are hematologic malignancies characterized by ineffective hematopoiesis. We study the molecular pathogenesis of MDS to identify targetable pathways for treatment of this disease.

Professional Interests

Key Words: cytokines, hematopoiesis, epigenetics, mds, leukemia, esophageal cancer, pancreatic cancer

1. Targeting signal transduction in hematologic malignancies: Cytokines play important roles in the regulation of normal hematopoiesis and a balance between the actions of hematopoietic growth factors and myelosuppressive factors is required for optimal production of different hematopoietic cell lineages. We study the role of MAP kinases in the regulation of hematopoiesis and have shown that the p38 MAPK signalling pathway is the dominant cytokine regulated inhibitory pathway in human hematopoiesis and is overactivated in MDS. The myelodysplastic syndromes (MDS) are collections of heterogeneous hematologic diseases characterized by refractory cytopenias due to ineffective hematopoiesis. These preleukemic disorders are common causes of anemia in the elderly and are rapidly increasing in incidence. We have also demonstrated that the TGF-b pathways is overactivated in MDS. We are trying to study the molecular mechanisms that lead to the activation of these pathways in MDS and are using small molecule inhibitors in mouse models to target these pathways.

2. Epigenomic analysis of tumors: We are using high throughput assays to analyze DNA methylation across the genome and have optimized these assays to work with low amounts of DNA. We have successfully used these assays in conducting an integrative analysis of epigenetic and genetic alterations in MDS and esophageal cancer. We are now exploring alterations in DNA methylation in pancreatic cancer, myeloproliferative neoplasms and renal cell cancer.

3. Clinical studies in Myelodysplastic syndromes: We have a “center of excellence” clinic for patients with Myelodysplatic syndromes. We offer a variety of clinical trials for these patients (www.mdstreatment.com).

Selected Publications

  1. Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreryo L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will W, Wei S, Steidl U*, Verma A*,  * co-corresponding authors, “IL8-CXCR2 pathway inhibition as a novel therapeutic strategy against MDS and AML stem cells.”
    Blood. 2015, Mar 25. PMID: 25810490               
  2. Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Ben Neriah D, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W, Verma A, Steidl U, “Minimal reduction of PU.1 is sufficient to induce a preleukemic state and promote development of acute myeloid leukemia.”
    Nature Medicine, 2015 (In Print)
  3. Vardabasso C, Gaspar-Maia A, Hasson D, Pünzeler S, Valle-Garcia D, Straub T, Keilhauer EC, Strub T, Dong J, Panda T, Chung CY, Yao JL, Singh R, Segura MF, Fontanals-Cirera B, Verma A, Mann M, Hernando E, Hake SB, Bernstein E, “Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.”
    Mol Cell. 2015 Jun 3. PMID: 26051178
  4. PAK1 Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U, “PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.”
    Blood. 2015 Jul 13. PMID: 26170031
  5. Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y, “Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.”
    Br J Haematol. 2015 Jun 24. PMID: 26105212
  6. Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, Mullenders J, King B, Trimarchi T, Aranda-Orgilles B, Liu C, Shen S, Verma A, Jaenisch R, Aifantis I, “TET1 is a tumor suppressor of hematopoietic malignancy.”
    Nat Immunol. 2015 Apr 13. PMID: 25867473
  7. Saleiro D, Mehrotra S, Kroczynska B, Beauchamp EM, Lisowski P, Majchrzak-Kita B, Bhagat TD, Stein BL, McMahon B, Altman JK, Kosciuczuk EM, Baker DP, Jie C, Jafari N, Thompson CB, Levine RL, Fish EN, Verma A, Platanias LC, “Central Role of ULK1 in Type I Interferon Signaling.”
    Cell Reports 2015, Apr 28;11(4):605-17. PMID: 25892232
  8. Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, Chew TL, Green KJ, Munshi HG, Verma AK, Platanias LC, “Human Schlafen 5 (SLFN5) is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells.”
    Mol Cell Biol. 2015 May 26. PMID: 26012550
  9. Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jädersten M, Dolatshad H, Verma A, Cross NC, Vyas P, Killick S, Hellström-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J, “Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.” 
    Nat Commun. 2015 Jan 9;6:5901. PMID: 25574665
  10. Caescu CI, Guo X, Tesfa L, Bhagat TD, Verma A, Zheng D, Stanley ER, “Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21.”
    Blood. 2015 Jan 8. PMID: 25573988
  11. Sridharan A, Jain R, Bachhuber MA, Yu Y, Ramesh Kh, Gundabolu K, Friedman EW, Verma AK, “Epidemiologic study of myelodysplastic syndromes in a multiethnic, inner city cohort.”
    Exp Hematol Oncol. 2014 Aug 23;3:22. PMID: 25170429
  12. Shrivastava MS, Hussain Z, Giricz O, Shenoy N, Polineni R, Maitra A, Verma A, “Targeting chemokine pathways in esophageal adenocarcinoma.”
    Cell Cycle. 2014 Nov 1;13(21):3320-7. PMID: 25485576
  13. Hu C, Mohtat D, Yu Y, Ko YA, Shenoy N, Bhattacharyya S, Izquierdo MC, Park AS, Giricz O, Vallumsetla N, Gundabolu K, Ware K, Bhagat T, Suzuki M, Pullman J, Liu SX, Greally J, Susztak K, Verma A, “Kidney cancer is characterized by aberrant methylation of tissue specific enhancers that are prognostic for overall survival.”
    Clin Cancer Res. 2014 Jun 10. PMID: 24916699
  14. Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, Bhattacharyya S, Wenger R, Cohn S, Nanduri J, Verma A, Prabhakar N, Godley LA, “TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma.”
    Cell Rep. 2014 May 14. PMID: 24835990
  15. Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris CE, Gao J, Basiorka AA, Schipma MJ, McElherne J, Yang J, Verma AK, Pellagatti A, Boultwood J, List AF, Williams DA, Ji P., “Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) myelodysplastic syndromes.”  
    Blood. 2014 Jun 2. PMID: 24891322
  16. Tamari R,  Schinke C, Bhagat T, Roth M, Braunschweig I,  Will B,  Steidl U, Verma A, “Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.”
    Leuk Lymphoma, 2014 Dec;55(12):2901-6.PMID: 24650011
  17. Bartholdy B, Christopeit M, Will B, Mo Y, Barreyro L, Yu Y, Bhagat T, Okoye-Okafor U, Todorova T, Greally J, Levine RL, Melnick A, Verma A*, Steidl U, *Co-Corresponding, “A human hematopoietic stem cell-commitment related DNA cytosine methylation signature is prognostic for overall survival in acute myeloid leukemia.”
    Journal of Clinical Investigation 2014 Feb 3 PMID: 24487588
  18. Msaouel P, Lam AP, Gundabolu K, Chrysofakis G, Yu Y, Mantzaris I, Friedman E, Verma A,  “Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity.”
    Haematologica, 2014 Feb 7. PMID: 24510340
  19. Kuo P, Leshchenko V, Fazzari M, Gellen T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh K, Goy A, Yang D, Chan W, Kahl B, Verma A, Gascoyne R, Kimby E, Sander B, Ye BH, Melnick A, Perumal D, He T, Parekh S, “High resolution Chromatin Immunoprecipitation (ChIP) sequencing reveals novel bindings targets and prognostic role for SOX11 in Mantle cell lymphoma.” 
    Oncogene, 2014 Mar 31 PMID: 24681958
  20. Hosono N, Makishima H, Jerez A, Yoshida K, Przychodzen B, McMahon S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Gómez-Seguí I, Verma AK, McDevitt MA, Sekeres MA, Ogawa S, Maciejewski JP, “Recurrent genetic defects on chromosome 7q in myeloid neoplasms.”
    Leukemia 2014 Jan 16. PMID: 24429498
  21. Madzo J, Liu H, Rodriguez A, Vasanthakumar A, Sundaravel S, Caces DB, Looney TJ, Zhang L, Lepore JB, Macrae T, Duszynski R, Shih AH, Song CX, Yu M, Yu Y, Grossman R, Raumann B, Verma A, He C, Levine RL, Lavelle D, Lahn BT, Wickrema A, Godley LA, “Hydroxymethylation at Gene Regulatory Regions Directs Stem/Early Progenitor Cell Commitment during Erythropoiesis.” 
    Cell Reports 2013 Dec 24 PMID: 24373966
  22. Ko YA, Mohtat D, Suzuki M, Park AS, Izquierdo MC, Han SY, Kang HM, Si H, Hostetter T, Pullman JM, Fazzari M, Verma A, Zheng D, Greally JM, Susztak K, “Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development.” 
    Genome Biol. 2013 Oct 7;14(10):R108. PMID: 24098934
  23. Pellagatti A, Benner A, Mills K, Cazzola M, Giagounidis AAN, Perry J, Malcovati L, Giovanni M, Porta D, Jädersten M,  Verma A, McDonald E, Killick S, Hellstrom-Lindberg E, Bullinger L, Wainscoat JS, Boultwood J, “Identification of gene expression based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.” 
    JCO 2013 Oct 1;31(28):3557-64. PMID: 24002510
  24. Lam AP, Gundabolu K, Sridharan A, Jain R, Msaouel P, Chrysofakis G, Yu Y, Friedman E, Price E, Schrier S, Verma AK,  “Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia.”
    Am J Hematol. 2013 Nov;88(11):E245-9. PMID: 23828763
  25. Yang X, Song JH, Cheng Y, Wu W, Bhagat T, Yu Y, Abraham JM, Ibrahim S, Ravich Roland W, Khashab M, Singh VK, Shin EJ, Yang X, Verma A, Meltzer SJ, Mori Y, “Long Noncoding RNA HNF1A-AS1 Regulates Proliferation and Migration in Esophageal Adenocarcinoma Cells.”
    Gut 2013 Sep 2. PMID: 24000294 
  26. Bajpai M, Kessel R, Bhagat T, Nischal S, Yu Y, Verma A*, Das K, *Co-Corresponding,  “High resolution integrative analysis reveals widespread genetic and epigenetic changes after chronic in-vitro acid and bile exposure in Barrett's epithelium cells.” 
    Genes Chromosome Cancer 2013 Oct 3. PMID: 24123713
  27. Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, McMahon B, Altman JK, Licht JD, Baker DP, Eklund EA, Wickrema A, Verma A, Fish EN, Platanias LC, “Essential role for the Mnk-pathway in the inhibitory effects of Type I interferons on myeloproliferative neoplasm (MPN) precursors.” 
    JBC, 2013 Aug 16;288(33):23814-22 PMID: 23814052
  28. Bhattacharyya, Si; Yu, Y; Suzuki, M; Campbell, N; Mazdo, J; Vasantkumar, A; Bhagat, T; Nischal, S; Christopeit, M; Parekh, S; Steidl, U; Godley, L; Maitra, A; Greally, J; Verma, A;  “Genome wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer.” 
    Nucleic Acid Res 2013  Sep;41(16):e157 PMID: 23861445
  29. Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD, Verma A, Figueroa ME, Melnick A, Roth M, Steidl U, “Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment.” 
    Nat Immunol. 2013 May;14(5):437-45. PMID: 23563689
  30. Bhagat T, Zhou L, Sokol L, Caceres G, Gundabolu K, Gordon S, Mantzaris I, Gligich O, Yu Y, Bhattacharyya S, Jing X, Polineni R, Tamari R, Bhatia K, Pellagatti A , Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A,  “miR-21 mediates hematopoietic suppression in MDS by activating TGF-b signaling.” 
    Blood 2013, Apr 11;121(15):2875-81. PMID: 23390194
  31. Yu Y, Mo Y, Liu H, Bhattacharyya S, Ebenezer D, Sundaravel S, Caces B, Ulaszek J, Artz A, Nischal S, Bhagat T, Bathon K, Maqbool S, Suzuki M, Steidl U, Godley L, Skoultchi A, Greally J, Wickrema A, Verma A, “High resolution methylome analysis reveals widespread hypomethylation during human erythroid differentiation.” 
    JBC 2013 Mar 29;288(13):8805-14. PMID: 23306203
  32. Heuck C, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A*, Singhal S,* Co-Corresponding, “Myeloma is characterized by stage specific alterations in DNA methylation that occur early during myelomagenesis.”   Journal of Immunology 2013 Mar 15;190(6):2966-75. PMID: 23408834
  33. Wu W, Bhagat T, Yang X, Song J, Cheng Y, Agarwal R, Abraham J, Ibrahim S, Bartenstein M, Hussain Z, Suzuki M, Yu Y, Eng C, Greally J, Verma A*, Meltzer SJ*, Co-Corresponding, “Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett’s Esophagus and Esophageal Adenocarcinoma.”  
    Gastroenterology 2013 May;144(5):956-966. PMID: 23333711
  34. Nischal S, Bhattacharyya S, Christopeit N, Yu Y, Zhou L, Bhagat T, Sohal S, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski J, Melnick A, Greally J, Steidl U, Moliterno A, Verma A,  “Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.” 
    Cancer Res, 2012 Dec 27. PMID: 23066032
  35. Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C,Tamari R, Yu Y, Bhagat T,  Bhattacharya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U, Verma A,  “Stem and progenitor cells in myelodysplastic syndromes show aberrant stage specific expansion and harbor genetic and epigenetic alterations.” 
    Blood 2012; 120(10):2076-86. PMID: 22753872
  36. Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF, “Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.” 
    Leukemia. 2012 Sep 11. PMID: 23032694
  37. Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U., “Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.” 
    Blood. 2012 May 24. PMID: 22627766
  38. Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U, “Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.” 
    Blood. 2012 Aug 9;120(6):1290-8. PMID: 22723552
  39. Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP,  “Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.”  
    Blood. 2012 Jun 21;119(25):6109-17. PMID: 22553315
  40. Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U, Verma A., “Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.” 
    Leuk Lymphoma.2012 Apr 18.  PMID: 22448921
  41. Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR, “Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.” 
    Haematologica. 2011 Oct;96(10):1462-9. Epub 2011 Jun 28. PMID: 21712540
  42. Sharma B, Altman JK, Goussetis DJ, Verma AK, Platanias LC, “Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis.” 
    J Biol Chem. 2011 Aug 5;286(31):27506-14. Epub 2011 Jun 9. PMID:1659535
  43. Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kanbhampati S, Parmar S, Nischal S, Heuck C, Suzuki M, Friedman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, Gore SD, Platanias LC, Levine R, Melnick A, Wickrema A, Greally JM, Verma A,  “Aberrant epigenetic and genetic marks are seen in myelodysplastic leucocytes and reveal DOCK4 as a candidate pathogenic gene on chr7q.” 
    J Biol Chem. 2011 Apr 30. PMID: 21532034 
  44. Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari M, Yu Y, Montagna C, Montgomery E, Canto M, Dunbar K, Wang J, Roa J, Mo Y, Bhagat T, Ramesh K, Cannizzaro L, Mollenhauer J, Thompson R, Suzuki M, Meltzer S, Melnick A, Greally JM, Maitra A, Verma A, “Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.” 
    PLOS Genetics 2011 Mar;7(3) PMID: 21483804
  45. L Zhou, C McMahon, T Bhagat, C Alencar, Y Yu, M Fazzari, D Sohal, C Heuck, K Gundabolu, C Ng, Y Mo, W Shen, A Wickrema, G Kong, E Friedman, L Sokol,  G Mantzaris, A Pellagatti , J Boultwood, LC Platanias, U Steidl, L Yan, JM Yingling, MM Lahn, A List, M Bitzer and A Verma, “Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.”
    Cancer Research 2011 Feb 1;71(3):955-63.PMID: 21189329
  46. Joshi S, Sharma B, Kaur S, Majchrzak B, Ueda T, Fukunaga R, Verma AK, Fish EN, Platanias LC, “Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis.” 
    J Biol Chem. 2011 Feb 25;286(8):6017-26.PMID: 21149447
  47. Kroczynska B, Joshi S, Eklund EA, Verma A, Kotenko SV, Fish EN, Platanias LC, “Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλ signaling.”
    J Biol Chem. 2011 Jan 14;286(2):1147-56. Epub 2010 Nov 12.
  48. Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang Y, Verma A, Theil KS, McDevitt MA, Maciejewski JP, “Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.”
    Genes Chromosomes Cancer. 2010 Apr;49(4):390-9. PMID: 20095039
  49. Schinke C, Goel S, Bhagat TD, Zhou L, Mo Y, Gallagher R, Kabalka GW, Platanias LC, Verma A*, Das B, “Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia.”
    Leuk Lymphoma. 2010 Jun;51(6):1108-14. PMID: 20536349
  50. Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Verma A, Norbury C Hellström-Lindberg E, Wainscoat JS, Boultwood J, “Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.”
    Leukemia. 2010 Apr;24(4):756-64. PMID: 20220779
  51. Einstein F, Thompson RF, Bhagat TD, Fazzari MJ, Verma A, Barzilai N, Greally JM, “Cytosine methylation dysregulation in neonates following intrauterine growth restriction.”
    LoS One. 2010 Jan 26;5(1):e8887 PMID: 20126273
  52. Oda M., Glass J.L., Thompson R.F., Mo Y., Olivier E., Figueroa M.E., Selzer R.R., Richmond T.A., Zhang X., Dannenberg L., Green R., Melnick A., Hatchwell E., Bouhassira E., Verma A., Suzuki M., Greally J.M., “High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers.”
    Nucleic Acids Res. 2009 Jul;37(12):3829-39.   PMID: 19386619
  53. Sohal D, Yeatts A, Ye K, Pellagatti A, Zhou L, Pahanish P, Mo Y, Bhagat T, Mariadason J, Boultwood J, Melnick A, Greally JM, Verma A, “Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration.”
    PLOS One 2008 Aug 13;3(8):e2965    PMID: 18698424
  54. Zhou L, Nguyen AN, Sohal D, Ma JY, Pahanish P, Gundabolu K, Hayman J, Chubak A,   Mo Y, Bhagat T, Das B, Haghnazari E, Navas T, Parmar S, Kambhampati S, Pellagati A,  Braunchweig I, Zhang YE, Wickrema A, Boultwood J, Platanias LC, Higgins LS, List A, Bitzer M, Verma A, “Inhibition of Transforming Growth Factor beta receptor I kinase can stimulate hematopoiesis in Myelodysplasia.”
    Blood 2008 Oct 15;112(8):3434-43  PMID: 18474728
  55. Navas T, Zhou L, Estes M, Haghnazari E, Nguyen A, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins L, Platanias LC, List A, Verma A, “Inhibition of p38a MAPK disrupts the pathological loop of proinflammatory factor production in the Myelodysplastic Syndrome bone marrow microenvironment.”
    Leukemia and Lymphoma 2008 Oct;49(10):1963-75
  56. Zhou L, Opalinska J, Verma A, “p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure.”
    Cell Cycle 2007, 1;6(5):534
  57. Navas T, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, Parmar S, Haghnazari E, Zhou L, Collins RC, Kerr I, Nguyen A, Xu Y, Platanias LC, List AA, Higgins LS, Verma A, “Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.”
    Blood 2006, 15;108(13):4170-7
  58. Verma A, and List A, “Cytokine Targets in Myelodysplastic syndromes.”
    Current Hematology Reports 2005 Nov;4(6):429-35
  59. Deonarain R, Verma A, Porter AC, Gewert DR, Platanias LC, Fish EN, “Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha.”
    Proc Natl Acad Sci USA. 2003 Nov 11;100(23):13453-8
  60. Verma A, Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, Van Besien K, “Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.”
    Bone Marrow Transplant. 2003 May;31(9):813-6.
  61. Verma A., Mohindru M., Deb D., Sassano A., Kambhampati S., Minucci S., Ravandi F., Kovakanalu D, Platanias L., “Activation of the Rac1 and p38 MAP kinase pathway in response to Arsenic trioxide.”
    Journal of Biological Chemistry 22;277(47):44988-95
  62. Verma A, Sassano A, Deb D, Wickrema, A., VanBesien K., and Platanias L., “Blockade of p38 MAP kinase reverses cytokine mediated inhibition in aplastic anemia.” 
    Journal of Immunology 2002, 168 (12) (Cutting edge section)
  63. Verma A, Deb D.K., Sassano A., Uddine S., Wickrema A., Varga and Platanias LC, “Activation of the p38 mitogen activated protein kinase mediates suppressive effects of Type I interferons and transforming growth factor-b on normal hematopoiesis.” 
    Journal of Biological Chemistry 2002, 277(10):7726-35
  64. Devine S, Hoffman R, Verma A, Shah R, Bradlow B, Stock W and Van Besien K, “Allogeneic blood cell transplantation following reduced intensity conditioning is effective therapy for older patients with myelofibrosis.”
    Blood  2002, 99(6):2255-8

 Review Articles

  1. Li W, Morrone K, Kambhampati S, Will B, Steidl U, Verma A
    “Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies”
    Leukemia, 2015 (In Press)
  2. Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C, Susztak K, Verma A.
    "Role of DNA methylation in renal cell carcinoma."
    J Hematol Oncol. 2015 Jul 22;8(1):88. PMID: 26198328
  3. Verma A, Steidl U.                                                                                                                                                                                                             “A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.”
    Nat Med. 2015;21:113-4.  PMID: 25654599
  4. Shenoy N, Vallumsetla N,  Rachmilewitz E, Verma A, Ginzburg Y.
    Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome
    Blood, 2014 Aug 7;124(6):873-81. PMID: 24923296
  5. Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G
    Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.
    Leukemia. 2015 Mar 12. PMID: 25761935
  6. Elias HK, Schinke C, Bhattacharyya S, Will B*, Verma A*,  Steidl U* *CoCorresponding
    “Stem cell origin of myelodysplastic syndromes.”
    Oncogene 2013 Dec 16. PMID: 24336326
  7. Das BC, Thapa P, Karki R, Das S, Mahapatra S, Liu TC, Torregroza I, Wallace DP, Kambhampati S, Van Veldhuizen P, Verma A, Ray SK,    Evans T.
    "Retinoic acid signaling pathways in development and diseases."
    Bioorg Med Chem. 2014 Jan 15;22(2):673-83. PMID: 24393720
  8. Pathak S, Roth M, Verma A*, Steidl U*.  *CoCorresponding
    “Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.”
    Expert Opin Drug Metab Toxicol. 2013 Dec;9(12):1667-75. PMID: 24215532
  9. Khan H, Vale C, Bhagat T, Verma A.
    “Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.”
    Semin Hematol. 2013 Jan;50(1):16-37. PMID: 23507481
  10. Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma AK
    “Linked-in: design and efficacy of antibody drug conjugates in oncology.”
    Oncotarget 2013 Mar;4(3):397-412. PMID: 23651630
  11. Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra A, Verma A.
    “Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.”
    Int J Clin Exp Pathol. 2012;5(5):382-96. PMID: 22808291
  12. Shenoy N, Kessel R, Bhagat TD, Bhattacharyya S, Yu Y, McMahon C, Verma A.
    “Alterations in the ribosomal machinery in cancer and hematologic disorders.”
    J Hematol Oncol. 2012 Jun 18;5:32. PMID: 22709827
  13. Elias H, Verma A
    “Activation of hypoxia signaling is marker of poor prognosis in myelodysplasia.”
    Leuk Lymphoma. 2012 Dec;53(12):2337-8. PMID: 22897726
  14. Sharma A,  Heuck C, Fazzari M, Mehta J, Singhal S, Greally JM, Verma A
    “DNA methylation alterations seen in myeloma as a model of epigenetic changes in cancer.”
    WIREs Systems Biology and Medicine 2010 Nov-Dec;2(6):654-69. PMID: 20890963
  15. Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally JM, Verma A
    Aberrant DNA methylation in malignant melanoma
    Melanoma Research 2010, Aug; 20(4):253-65 PMID: 20418788
  16. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A.
    “Mechanism of action of lenalidomide in hematological malignancies.”
    J Hematol Oncol. 2009 Aug 12;2:36
  17. Opalinska J, Zhou L, Verma A.
    “A new PML-RARs fusion transcript hints at the important role of PML dysregulation in the pathogenesis of APL.”
    Leukemia Research (Commentary) 2007, 48(3):443
  18. Isufi I, Seetharam M, Sohal D, Zhou L, Opalinska J, Pahanish P, Verma A.
    Transforming Growth Factor-beta Signaling in Normal and Malignant Hematopoiesis.
    Journal of Interferon and Cytokine Research 2007, 27(7):543
  19. Mohindru M, Verma A
    “Engineered antibodies act as targeted therapies in cancer treatment.”
    Indian Journal of Pediatrics, 2005 Nov;72(11):943-7
  20. Sassano A, Verma A, Platanias LC
    "Mitogen-activated protein kinase pathways in interferon signaling."
    Methods Molecular Medicine, 2005;116:135-50.
  21. Mohindru M, Verma A
    "Kinase inhibitors translate lab discoveries into exciting new cures for cancers."
    Indian Journal of Pediatrics, 2004 Aug;71(8):713-8.
  22. Verma A, Kambhampati S, Parmar S, Platanias LC.
    “Jak family of kinases in cancer.”
    Cancer Metastasis Rev. 2003 Dec;22(4):423-34.(rev)
  23. Verma A, and Platanias LC
    “Signaling via the interferon-a receptor in chronic myelogenous leukemia cells.”
    Leukemia and Lymphoma  2002, 44:703-709
  24. Verma A, and Stock W
    “Management of adult lymphoblastic leukemia: moving toward a risk-adapted approach.”
    Current Opinion in Oncology, 2001, 13:14-20
  25. Verma A, and Gupta YK
    “The search for a super oral rehydration solution (0RS).” 
    Drugs: News and Views, 1995, 3(2):129-132.

More Information About Dr. Amit Verma


Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.

Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
1300 Morris Park Avenue
Chanin Building, Room 302B
Bronx, NY 10461

Tel: 718.430.8761
Fax: 718.430.8702

Research Information